In May 2021, Manhattan, NY-headquartered Goldman Sachs alternative investing arm Goldman Sachs Asset Management acquired a significant minority stake in Hyderabad, India-based Aragen Life Sciences a contract research organization.
Goldman bought shares previously held by ChrysCapital and other existing shareholders who were invested in the company for more than five years and had had a successful exit.
Manni Kantipudi, CEO of Aragen Life Sciences, said, “We believe this new investment at this important juncture in our company’s development underscores the tremendous opportunity ahead.”
Goldman Sachs has been an active investor in India and has invested $3.6 billion since 2006. Its other healthcare bets include Biocon Biologics, BPL Medical Technologies, CyteCare Hospitals, Max India and Nova Medical Centers.
Rajat Sood, managing director at Goldman Sachs Asset Management, added that the firm is actively seeking to invest and foster leading national champions of India who are building companies of a global scale.
